Credit Suisse Group started coverage on shares of Inflarx (NASDAQ:IFRX) in a report released on Monday morning, MarketBeat reports. The firm issued an outperform rating and a $47.00 price objective on the stock.
Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Inflarx from a sell rating to a hold rating in a report on Tuesday, November 13th. ValuEngine raised shares of Inflarx from a hold rating to a buy rating in a report on Thursday, November 1st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Inflarx currently has an average rating of Buy and a consensus target price of $45.50.
Shares of NASDAQ IFRX opened at $29.50 on Monday. Inflarx has a 12 month low of $17.50 and a 12 month high of $42.83.
Several large investors have recently bought and sold shares of IFRX. Matisse Capital purchased a new position in shares of Inflarx during the 3rd quarter valued at approximately $203,000. Bank of New York Mellon Corp purchased a new position in shares of Inflarx during the 3rd quarter valued at approximately $277,000. Jane Street Group LLC purchased a new position in shares of Inflarx during the 3rd quarter valued at approximately $278,000. JPMorgan Chase & Co. increased its holdings in shares of Inflarx by 29.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock valued at $367,000 after purchasing an additional 2,420 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Inflarx by 46.9% during the 2nd quarter. Northern Trust Corp now owns 11,624 shares of the company’s stock valued at $375,000 after purchasing an additional 3,709 shares in the last quarter. 57.12% of the stock is owned by hedge funds and other institutional investors.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Story: Benefits of owning preferred stock
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.